SSR181507, a putative atypical antipsychotic with dopamine D2 antagonist and 5-HT1A agonist activities: Improvement of social interaction deficits induced by phencyclidine in rats

Neuropharmacology

Volumn 46, Issue 8, 2004, Pages 1121-1129

  Boulay, D ^a   Depoortere R ^a   Louis, C ^a   Perrault, G ^a   Griebel, G ^a   Soubrie P ^a  

^a SANOFI   (France)

Author keywords

5 HT1A Agonist; Atypical antipsychotic; DA D2 Antagonist; Phencyclidine; Social interaction deficit

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; HALOPERIDOL; PHENCYCLIDINE; SEROTONIN 1A AGONIST; SSR 181507;

ANIMAL EXPERIMENT; ARTICLE; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; SOCIAL BEHAVIOR; SOCIAL INTERACTION; SOCIOPATHY; TRANQUILIZING ACTIVITY;

ANIMALS; ANTIPSYCHOTIC AGENTS; DIOXANES; INTERPERSONAL RELATIONS; MALE; PHENCYCLIDINE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTORS, DOPAMINE D2; SOCIAL BEHAVIOR; TROPANES;

EID: 1942532867     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2004.02.008     Document Type: Article

References (47)

1. Andreasen N.C., Flaum M., Swayze V.W., Tyrrell G., Arndt S. Positive and negative symptoms in schizophrenia. A critical reappraisal. Arch. Gen. Psychiatry. 47:1990;615-621.
2. Aquila R., Weiden P.J., Emanuel M. Compliance and the rehabilitation alliance. J. Clin. Psychiatry. 60:(Suppl. 19):1999;23-27.
3. Barnes T.R., McPhillips M.A. How to distinguish between the neuroleptic-induced deficit syndrome, depression and disease-related negative symptoms in schizophrenia. Int. Clin. Psychopharmacol. 10:(Suppl. 3):1995;115-121.
4. Buchanan R.W., Kreyenbuhl J., Zito J.M., Lehman A. Relationship of the use of adjunctive pharmacological agents to symptoms and level of function in schizophrenia. Am. J. Psychiatry. 159:2002;1035-1043.
5. Campbell M., Young P.I., Bateman D.N., Smith J.M., Thomas S.H. The use of atypical antipsychotics in the management of schizophrenia. Br. J. Clin. Pharmacol. 47:1999;13-22.
6. Chemerinski E., Nopoulos P.C., Crespo-Facorro B., Andreasen N.C., Magnotta V. Morphology of the ventral frontal cortex in schizophrenia: relationship with social dysfunction. Biol. Psychiatry. 52:2002;1-8.
7. 1A receptor agonist. I: neurochemical and electrophysiological profile. Neuropsychopharmacology. 28:2003;2064-2076.
8. Corbett R., Camacho F., Woods A.T., Kerman L.L., Fishkin R.J., Brooks K., Dunn R.W. Antipsychotic agents antagonize non-competitive N-methyl-D-aspartate antagonist-induced behaviors. Psychopharmacology. 120:1995;67-74.
9. 1A receptor agonist. II: behavioral profile predictive of an atypical antipsychotic activity. Neuropsychopharmacology. 28:2003;1889-1902.
10. Dickerson F., Boronow J.J., Ringel N., Parente F. Neurocognitive deficits and social functioning in outpatients with schizophrenia. Schizophr. Res. 21:1996;75-83.
11. Escamilla M.A. Diagnosis and treatment of mood disorders that co-occur with schizophrenia. Psychiatr. Serv. 52:2001;911-919.
12. File S.E., Andrews N. Low but not high doses of buspirone reduce the anxiogenic effects of diazepam withdrawal. Psychopharmacology. 105:1991;578-582.
13. File S.E., Hyde J.R. Can social interaction be used to measure anxiety? Br. J. Pharmacol. 62:1978;19-24.
14. File S.E., Seth P. A review of 25 years of the social interaction test. Eur. J. Pharmacol. 463:2003;35-53.
15. Ichikawa J., Kuroki T., Dai J., Meltzer H.Y. Effect of antipsychotic drugs on extracellular serotonin levels in rat medial prefrontal cortex and nucleus accumbens. Eur. J. Pharmacol. 351:1998;163-171.
16. Ichikawa J., Meltzer H.Y. Relationship between dopaminergic and serotonergic neuronal activity in the frontal cortex and the action of typical and atypical antipsychotic drugs. Eur. Arch. Psychiatry Clin. Neurosci. 249:(Suppl. 4):1999;90-98.
17. Ichikawa J., Ishii H., Bonaccorso S., Fowler W.L., O'Laughlin I.A., Meltzer H.Y. 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J. Neurochem. 76:2001;1521-1531.
18. Itil T., Keskiner A., Kiremitci N., Holden J.M. Effect of phencyclidine in chronic schizophrenics. Can. Psychiatr. Assoc. J. 12:1967;209-212.
19. Javitt D.C. Negative schizophrenic symptomatology and the PCP (phencyclidine) model of schizophrenia. Hillside J. Clin. Psychiatry. 9:1987;12-35.
20. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry. 148:1991;1301-1308.
21. Kehne J.H., McCloskey T.C., Baron B.M., Chi E.M., Harrison B.L., Whitten J.P., Palfreyman M.G. NMDA receptor complex antagonists have potential anxiolytic effects as measured with separation-induced ultrasonic vocalizations. Eur. J. Pharmacol. 193:1991;283-292.
22. Kennett G.A., Dourish C.T., Curzon G. Antidepressant-like action of 5-HT1A agonists and conventional antidepressants in an animal model of depression. Eur. J. Pharmacol. 134:1987;265-274.
23. Koek W., Patoiseau J.F., Assie M.B., Cosi C., Kleven M.S., Dupont-Passelaigue E., Carilla-Durand E., Palmier C., Valentin J.P., John G., Pauwels P.J., Tarayre J.P., Colpaert F.C. F 11440, a potent, selective, high efficacy 5-HT1A receptor agonist with marked anxiolytic and antidepressant potential. J. Pharmacol. Exp. Ther. 287:1998;266-283.
24. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., Heninger G.R., Bowers M.B. Jr., Charney D.S. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry. 51:1994;199-214.
25. Lahti A.C., Koffel B., LaPorte D., Tamminga C.A. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology. 13:1995;9-19.
26. Larsson L.G., Stenfors C., Ross S.B. Differential regional antagonism of 8-OH-DPAT-induced decrease in serotonin synthesis by two 5-HT1A receptor antagonists. Eur. J. Pharmacol. 346:1998;209-215.
27. Li X.M., Perry K.W., Wong D.T., Bymaster F.P. Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum. Psychopharmacology. 136:1998;153-161.
28. McLaren S., Cookson J.C., Silverstone T. Positive and negative symptoms, depression and social disability in chronic schizophrenia: a comparative trial of bromperidol and fluphenazine decanoates. Int. Clin. Psychopharmacol. 7:1992;67-72.
29. Meltzer H.Y. Treatment of the neuroleptic-nonresponsive schizophrenic patient. Schizophr. Bull. 18:1992;515-542.
30. Meltzer H.Y., Burnett S., Bastani B., Ramirez L.F. Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hosp. Community Psychiatry. 41:1990;892-897.
31. Noda Y., Mamiya T., Furukawa H., Nabeshima T. Effects of antidepressants on phencyclidine-induced enhancement of immobility in a forced swimming test in mice. Eur. J. Pharmacol. 324:1997;135-140.
32. Overstreet D.H., Knapp D.J., Moy S.S., Breese G.R. A5-HT(1A) agonist and a 5-HT(2c) antagonist reduce social interaction deficit induced by multiple ethanol withdrawals in rats. Psychopharmacology. 167:2003;344-352.
33. Plaznik A., Stefanski R., Kostowski W. Restraint stress-induced changes in saccharin preference: the effect of antidepressive treatment and diazepam. Pharmacol. Biochem. Behav. 33:1989;755-759.
34. Porter J.H., Wiley J.L., Balster R.L. Effects of phencyclidine-like drugs on punished behavior in rats. J. Pharmacol. Exp. Ther. 248:1989;997-1002.
35. Qiao H., Noda Y., Kamei H., Nagai T., Furukawa H., Miura H., Kayukawa Y., Ohta T., Nabeshima T. Clozapine, but not haloperidol, reverses social behavior deficit in mice during withdrawal from chronic phencyclidine treatment. Neuroreport. 12:2001;11-15.
36. Sams-Dodd F. Distinct effects of D-amphetamine and phencyclidine on the social behaviour of rats. Behav. Pharmacol. 6:1995;55-65.
37. Sams-Dodd F. Effect of novel antipsychotic drugs on phencyclidine-induced stereotyped behaviour and social isolation in the rat social interaction test. Behav. Pharmacol. 8:1997;196-215.
38. Sams-Dodd F. Effects of diazepam, citalopram, methadone and naloxone on PCP-induced stereotyped behaviour and social isolation in the rat social interaction test. Neurosci. Biobehav. Rev. 23:1998a;287-293.
39. Sams-Dodd F. Effects of dopamine agonists and antagonists on PCP-induced stereotyped behaviour and social isolation in the rat social interaction test. Psychopharmacology. 135:1998b;182-193.
40. Sanchez C., Meier E. Behavioral profiles of SSRIs in animal models of depression, anxiety and aggression. Are they all alike? Psychopharmacology. 129:1997;197-205.
41. Schlemmer R.F., Davis J.M. A comparison of three psychotomimetic-induced models of psychosis in nonhuman primate social colonies. Prog. Clin. Biol. Res. 131:1983;33-78.
42. Silvestre J.S., Nadal R., Pallares M., Ferre N. Acute effects of ketamine in the holeboard, the elevated-plus maze, and the social interaction test in Wistar rats. Depress. Anxiety. 5:1997;29-33.
43. Steinpreis R.E., Sokolowski J.D., Papanikolaou A., Salamone J.D. The effects of haloperidol and clozapine on PCP- and amphetamine-induced suppression of social behavior in the rat. Pharmacol. Biochem. Behav. 47:1994;579-585.
44. Thomson A.M., West D.C., Lodge D. An N-methylaspartate receptor-mediated synapse in rat cerebral cortex: a site of action of ketamine? Nature. 313:1985;479-481.
45. Volonté M., Monferini E., Cerutti M., Fodritto F., Borsini F. BIMG 80, a novel potential antipsychotic drug: evidence for multireceptor actions and preferential release of dopamine in prefrontal cortex. J. Neurochem. 69:1997;182-190.
46. Wible C.G., Anderson J., Shenton M.E., Kricun A., Hirayasu Y., Tanaka S., Levitt J.J., O'Donnell B.F., Kikinis R., Jolesz F.A., McCarley R.W. Prefrontal cortex, negative symptoms, and schizophrenia: an MRI study. Psychiatry Res. 108:2001;65-78.
47. Xie Z., Commissaris R.L. Anxiolytic-like effects of the noncompetitive NMDA antagonist MK 801. Pharmacol. Biochem. Behav. 43:1992;471-477.